Organ systems

TruEats Partners with Beyond Type 1 to Empower People Living with Diabetes Through Funded Programs and Enhanced Resources

Retrieved on: 
Thursday, July 8, 2021
Health, Organ systems, Diabetes, Disability

The partnership between Beyond Type 1 and TrueEats is long standing, and together the organizations support people with diabetes by providing both resources and programming, including the Diabetes Scholars Program .

Key Points: 
  • The partnership between Beyond Type 1 and TrueEats is long standing, and together the organizations support people with diabetes by providing both resources and programming, including the Diabetes Scholars Program .
  • Founded by Dr. Surinder Kumar and his son Daven, the line is inspired by Dr. Kumar's late father who suffered from Type 1 Diabetes.
  • "Our passion is to positively affect the lives of those living with Type 1 and Type 2 diabetes.
  • "We are particularly proud of our participation in the organization's Diabetes Scholars program, which provides scholarships for deserving students with Type 1 Diabetes.

China Launches the World's Largest Real-World Study on Screening and Diagnosis of Male Reproduction-Related Genes

Retrieved on: 
Wednesday, July 7, 2021
Organ systems, Fertility medicine, Branches of biology, Male genital disorders, Testicular infertility factors, Medical specialties, Azoospermia, Male infertility, Hypogonadism, Infertility, Isolated hypogonadotropic hypogonadism, Oligospermia

This project is currently the world's largest real-world research project on male reproduction-related genes.

Key Points: 
  • This project is currently the world's largest real-world research project on male reproduction-related genes.
  • This real-world study will complete a database of at least 100,000 high-quality samples and phenotypes of reproduction-related genes of Chinese males within 3 years.
  • These phenotypes include non-obstructive azoospermia and severe oligospermia, obstructive azoospermia, teratozoospermia, disorders of sexual development, idiopathic hypogonadotropic hypogonadism and other common causes of clinical male infertility.
  • The database will uncover the mutation frequency, distribution and phenotypic characteristics of Chinese male infertility-related genes.

Neurana Pharmaceuticals Announces Publication in Pain Management

Retrieved on: 
Wednesday, July 7, 2021
Muscle relaxants, Drugs, Piperidines, Acute pain, Palliative care, Tolperisone, Pain management, Organ systems

SAN DIEGO, July 7, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the publication of a manuscript, "RESUME-1: A Phase III Study of Tolperisone in Treatment of Painful, Acute Muscle Spasms of the Back" in the journal of "Pain Management".

Key Points: 
  • SAN DIEGO, July 7, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the publication of a manuscript, "RESUME-1: A Phase III Study of Tolperisone in Treatment of Painful, Acute Muscle Spasms of the Back" in the journal of "Pain Management".
  • The study is designed to evaluate the efficacy and safety of tolperisone administered in subjects with pain due to acute back muscle spasms.
  • Key secondary objectives include assessing the tolerability, onset of action, and need for rescue medication when treated with tolperisone.
  • Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back.

Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021

Retrieved on: 
Wednesday, July 7, 2021
Dipraglurant, Imidazopyridines, Organofluorides, Organ systems, Pharmacology, Dystonia, Blepharospasm, Pharmaceutical industry, Health

Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021.

Key Points: 
  • Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021.
  • Mr. Dyer will give a corporate update, including an overview of recent advances in Addexs clinical trial program.
  • To learn more about the event or to schedule a one-on-one meeting with Addex management, please visit https://www.accesstogiving.com/ or email [email protected] .
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.

Luvme Hair Supporting E-Beauty's Wig Donation Program to Empower Women Undergoing Chemotherapy

Retrieved on: 
Wednesday, July 7, 2021
Organ systems, Clinical medicine, Medicine, Cancer treatments, Human hair, Hairdressing, Hair loss, Chemotherapy, Wig, Hair

NEW YORK, July 6, 2021 /PRNewswire/ -- Luvme Hair, a luxury human hair wig brand, has focused on women's health issues for many years.

Key Points: 
  • NEW YORK, July 6, 2021 /PRNewswire/ -- Luvme Hair, a luxury human hair wig brand, has focused on women's health issues for many years.
  • They kicked off their wig donation drive to benefit the women undergoing chemotherapy treatments.
  • According to pharmacy times, approximately 65% of individuals undergoing chemotherapy will experience chemotherapy-induced hair loss.
  • Forty-seven percent of female cancer patients consider hair loss to be the most traumatic aspect of chemotherapy, with 8% of them stating they would decline treatment for fear of hair loss.To support and empower our global community, Luvme Hair plans to help these women in need overcome their hair loss due to chemotherapy through their wig donations program.

FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients

Retrieved on: 
Tuesday, July 6, 2021
Arthritis, Osteoarthritis, Intractable pain, Pain management, Organ systems, Health sciences, Clinical medicine

The phase 2 trial, a multi-center, double blind, placebo- and active-controlled study, will assess the efficacy and safety of several dose groups of RTX to manage pain in patients with moderate-to-severe osteoarthritis of the knee pain (OAK) (clinicaltrials.gov: NCT04885972).

Key Points: 
  • The phase 2 trial, a multi-center, double blind, placebo- and active-controlled study, will assess the efficacy and safety of several dose groups of RTX to manage pain in patients with moderate-to-severe osteoarthritis of the knee pain (OAK) (clinicaltrials.gov: NCT04885972).
  • Given the durability of OA pain relief response to RTX demonstrated thus far, Sorrento has decided to include an active comparator (injectable corticosteroid) in the current trial protocol.
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.
  • SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.

Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Retrieved on: 
Tuesday, July 6, 2021
Ophthalmology, Organ systems, Vision, Blindness, Macular edema, Diabetic retinopathy, Macular degeneration, Eye surgery, Adverum Biotechnologies, Anti–vascular endothelial growth factor therapy

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Key Points: 
  • Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
  • There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage.
  • Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities.
  • Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises.

Diabetic Retinopathy Market Insight, Epidemiology and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Pharmaceutical, Health, Cardiology, Diabetes, Organ systems, Blindness, Diabetic retinopathy, Health, Retinopathy, Clinical medicine

The "Diabetic Retinopathy - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetic Retinopathy - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Diabetic Retinopathy (DR) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Diabetic Retinopathy (DR) symptoms market size from 2018 to 2030 segmented by seven major markets.
  • The report also covers current Diabetic Retinopathy (DR) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
  • The Diabetic Retinopathy (DR) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Diabetic Retinopathy (DR) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

Almirall and MC2 Therapeutics announce completion of decentralized procedure in Europe for the topical treatment of mild to moderate psoriasis vulgaris in adults

Retrieved on: 
Tuesday, July 6, 2021
Psoriasis, Organ systems, Autoimmune diseases, Medical specialties, Pustular psoriasis

"Our commitment to patients and to address unmet needs in skin diseases is reinforced today after the completion of the decentralized procedure.

Key Points: 
  • "Our commitment to patients and to address unmet needs in skin diseases is reinforced today after the completion of the decentralized procedure.
  • The topical treatment is the perfect addition to our growing psoriasis portfolio, which includes multiple treatment options that cover the whole spectrum of the disease.
  • The successful completion of a decentralized procedure is the final step before national marketing authorizations can be granted by the European countries.
  • The negative impact of psoriasis on people's lives can be immense as it affects the appearance of the skin with red, scaly plaques.

DGAP-News: APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401

Retrieved on: 
Tuesday, July 6, 2021
Immune system, Treatment of cancer, Immune checkpoint, Organ systems, Medical specialties, Clinical medicine, Heat Biologics, APN401, APEIRON Biologics AG, APN401, APEIRON BIOLOGICS AG

Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors

Key Points: 
  • Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors
    Vienna, Austria, 06 July 2021: APEIRON Biologics AG announced today the start of a Phase Ib clinical trial with its product candidate APN401 for the treatment of solid tumors.
  • The principle of cell therapy with APN401 by inhibiting the immune checkpoint Cbl-b aims at the patient's own immune cells.
  • The open-label, multi-center Phase Ib clinical trial is expected to enroll approximately 60 patients at multiple sites in Austria.
  • Peter Llewellyn-Davies, CEO of APEIRON Biologics AG, says: "We are thrilled to be contributing a groundbreaking cancer treatment with this truly pioneering step in development of our APN401 cell therapy.